EP2331057A2 - Compositions and methods for modulating skin pigmentation - Google Patents
Compositions and methods for modulating skin pigmentationInfo
- Publication number
- EP2331057A2 EP2331057A2 EP09736640A EP09736640A EP2331057A2 EP 2331057 A2 EP2331057 A2 EP 2331057A2 EP 09736640 A EP09736640 A EP 09736640A EP 09736640 A EP09736640 A EP 09736640A EP 2331057 A2 EP2331057 A2 EP 2331057A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- alk6
- cdc42
- bmp6
- expression
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 92
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 208000012641 Pigmentation disease Diseases 0.000 title abstract description 14
- 210000002752 melanocyte Anatomy 0.000 claims abstract description 95
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 94
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 claims abstract description 93
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 claims abstract description 87
- 102000011068 Cdc42 Human genes 0.000 claims abstract description 74
- 108050001278 Cdc42 Proteins 0.000 claims abstract description 74
- 230000014509 gene expression Effects 0.000 claims abstract description 70
- 210000002510 keratinocyte Anatomy 0.000 claims abstract description 62
- 239000000126 substance Substances 0.000 claims abstract description 60
- 238000012546 transfer Methods 0.000 claims abstract description 57
- 230000000694 effects Effects 0.000 claims abstract description 54
- 210000003491 skin Anatomy 0.000 claims abstract description 34
- 230000019612 pigmentation Effects 0.000 claims abstract description 11
- 101000899390 Homo sapiens Bone morphogenetic protein 6 Proteins 0.000 claims description 138
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 claims description 116
- 210000004027 cell Anatomy 0.000 claims description 75
- 238000012360 testing method Methods 0.000 claims description 38
- 102000019307 Sclerostin Human genes 0.000 claims description 36
- 108050006698 Sclerostin Proteins 0.000 claims description 36
- 239000005557 antagonist Substances 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 20
- 108020004999 messenger RNA Proteins 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 15
- 210000004209 hair Anatomy 0.000 claims description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 11
- 239000002537 cosmetic Substances 0.000 claims description 9
- 230000009368 gene silencing by RNA Effects 0.000 claims description 8
- 108091030071 RNAI Proteins 0.000 claims description 5
- 230000004913 activation Effects 0.000 claims description 5
- 230000000692 anti-sense effect Effects 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 102100029379 Follistatin-related protein 3 Human genes 0.000 claims description 4
- 101001062529 Homo sapiens Follistatin-related protein 3 Proteins 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- 208000019000 darkening of skin Diseases 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 238000003556 assay Methods 0.000 abstract description 9
- 241000282414 Homo sapiens Species 0.000 description 56
- 210000002780 melanosome Anatomy 0.000 description 38
- 150000001413 amino acids Chemical class 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 25
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 21
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 229940112869 bone morphogenetic protein Drugs 0.000 description 20
- 230000003061 melanogenesis Effects 0.000 description 20
- 108020003175 receptors Proteins 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 19
- 238000003501 co-culture Methods 0.000 description 18
- 102000003425 Tyrosinase Human genes 0.000 description 17
- 108060008724 Tyrosinase Proteins 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 102000046095 human BMP6 Human genes 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 102000008154 Bone Morphogenetic Protein 6 Human genes 0.000 description 10
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 238000010166 immunofluorescence Methods 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 102000058171 human SOST Human genes 0.000 description 8
- 229920001213 Polysorbate 20 Polymers 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 230000036564 melanin content Effects 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 5
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 4
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 4
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 4
- 238000010240 RT-PCR analysis Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 102000013515 cdc42 GTP-Binding Protein Human genes 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 230000003793 hair pigmentation Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- -1 Aromatic amino acids Chemical class 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000003305 autocrine Effects 0.000 description 3
- 238000004422 calculation algorithm Methods 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 238000004626 scanning electron microscopy Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 2
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 206010064127 Solar lentigo Diseases 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000012881 co-culture medium Substances 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000000254 damaging effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000933 neural crest Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 1
- 102100034111 Activin receptor type-1 Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101150072730 Bmp6 gene Proteins 0.000 description 1
- 101710120270 Bone morphogenetic protein receptor type-1A Proteins 0.000 description 1
- 101710120271 Bone morphogenetic protein receptor type-1B Proteins 0.000 description 1
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 description 1
- 108050008407 Bone morphogenetic protein receptor type-2 Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 101800001318 Capsid protein VP4 Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100025051 Cell division control protein 42 homolog Human genes 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000003367 Hypopigmentation Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100437777 Mus musculus Bmpr1a gene Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102100036901 SLC2A4 regulator Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NUFNQYOELLVIPL-UHFFFAOYSA-N acifluorfen Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(OC=2C(=CC(=CC=2)C(F)(F)F)Cl)=C1 NUFNQYOELLVIPL-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 238000010217 densitometric analysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 229940094991 herring sperm dna Drugs 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000003425 hypopigmentation Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000008684 selective degradation Effects 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/08—Preparations for bleaching the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/10—Preparations for permanently dyeing the hair
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Definitions
- the present invention relates to compositions and methods useful in studying or modulating melanin pigmentation in the skin. Particularly, but not exclusively, the invention relates to compositions capable of modulation of the transfer of melanin from melanocytes to keratinocytes and potentially from keratinocytes to keratinocytes, assays for identifying such compositions, and methods of modulating skin pigmentation.
- Melanocytes are neural crest-derived cells distributed along the basal layer of the epidermis and hair bulb. These cells synthesize melanin pigment within unique melanocyte-specific organelles called melanosomes. For skin and hair to become pigmented this melanin must be transferred from melanocytes to adjacent keratinocytes. Mammalian skin and hair/wool/fur colour is determined by melanin quantity and quality (brown/black eumelanin or red/yellow pheomelanin) in a process that involves a large number of steps regulated at multiple control points by a range of different molecules and compounds.
- BMP6 Bone morphogenetic proteins
- BMP receptors (Wozney et al., 1988). BMP signalling operates at multiple levels depending on BMP type, presence of antagonist(s), development stage of target tissue, and target cell receptor type (Botchkarev 2003). BMPs bind two transmembrane receptor families, multiple BMP receptor (BMPR)I and a single BMPRII (Hogan 1996). Interestingly, to initiate signalling, BMP has to bind both receptors, inducing phosphorylation of an intracellular domain in BMPRI by BMP-RII and activating intracellular signal transduction.
- BMPR multiple BMP receptor
- BMPs are powerful regulators of cutaneous development, and they also play important roles in the control of epidermal homeostasis, hair follicle growth, and melanogenesis in normal postnatal skin (Botchkarev 2003).
- Melanocytes are neural crest-derived cells that migrate to the epidermis and hair follicles during embryogenesis and subsequently synthesize and distribute melanin to surrounding keratinocytes (Halaban et al 2003).
- BMPRI receptors BMPRIA (ALK3; Seq ID 4), BMPRIB (ALK6; Seq ID 2), and ActR-l (ALK2) (Kawabata et al., 1998) and in neural precursor cells signalling through ALK3 induces their proliferation while ALK6 induces their differentiation (Panchision et al., 2001 ), suggesting that receptor expression determines the BMP effect on cells.
- BMP4 in melanocyte biology was first shown by the Gilchrest group in a study showing that this particular BMP family member acted as an autocrine inhibitor of melanogenesis in normal human melanocytes by inhibiting the expression and activity of the rate-limiting enzyme (tyrosinase) in melanocytes (Yaar et al., 2006).
- a method of modulating melanin pigmentation of the skin and/or hair of a subject comprising administering to a subject a composition comprising a substance capable of modulating the activity or expression of ALK6 (SEQ ID 2) or Cdc42.
- the substance modulates the expression of Cdc42 through modulating the activity of ALK6.
- the method involves application of the composition to the outer surface of the skin and/or hair of a subject.
- modulating melanogenesis and modulating transfer of melanin.
- the present invention can involve one, other or both of these approaches.
- methods which modulate melanin transfer are of particular interest as the present inventors have discovered that melanin transfer can be effectively targeted. Given that it is a further "downstream" process than melanogenesis, it is a more attractive target in terms of avoiding adverse effects.
- the method is a cosmetic method, which is useful for cosmetic lightening or darkening of skin and/or hair colour through modulating the level of melanin pigmentation of the skin and/or hair.
- the method may be used to provide a degree of photoprotection to the subject. It is well known that melanin protects the skin from many of the damaging effects of ultraviolet radiation. Accordingly, increasing the amount of melanin in the skin of a subject may be significant in reducing sunlight induced damage, e.g. mutation of a cell potentially leading to cancer or premature ageing.
- the method may be used to treat a medical condition associated with abnormal pigmentation of the skin. Such treatment may be curative, or it might be used in order to lesson symptoms.
- Diseases or medical conditions associated with altered pigmentation of the skin which could be treated include hyperpigmentation (e.g., melasma, chloasma, senile lentigo, solar lentigo, ephelides, postinflammatory hyperpigmentation) and hypopigmentation (e.g, vitiligo, and post-inflammatory hypopigmentation) and pigmentation loss as a result of skin damage.
- the substance is capable of increasing the activity or expression of ALK6 relative to normal physiological levels, i.e. an ALK6 agonist.
- the substance is capable of increasing the activity or expression of ALK6 in a manner which increases melanin transfer. An increase in ALK6 activity would lead to increased melanin in the skin and/or hair.
- the substance is capable of decreasing the activity or expression of ALK6 relative to normal physiological levels, i.e. an ALK6 antagonist.
- the substance is capable of decreasing the activity or expression of ALK6 in a manner which decreases melanin transfer. A decrease in ALK6 activity would lead to decreased melanin in the skin and/or hair.
- the present invention method involves application of a composition comprising a BMP6 polypeptide (accession number NM_001718; Seq ID 1 ) or a fragment or variant thereof, wherein said fragment or variant is functionally active.
- a composition comprising a BMP6 polypeptide (accession number NM_001718; Seq ID 1 ) or a fragment or variant thereof, wherein said fragment or variant is functionally active.
- a fragment or variant can be said to be functionally active where it is able to activate ALK6 at least 50% as efficiently as wild type BMP6, though lower levels of activity may still be useful. More preferably such a fragment or variant should be at least 75% as active as wild type BMP6, especially 90% as active as wild type BMP6.
- active in this context can mean the ability to stimulate the transfer of melanin from melanocytes to keratinocytes in the assays described below.
- a "functionally active" BMP6 fragment or variant exhibits the ability to increase melanogenesis or melanin transfer as determined using the assays described later.
- the functional activity of BMP6 proteins, variants and fragments can be assayed by various methods known to one skilled in the art (Current Protocols in Protein Science (1998) Coligan et al., eds., John Wiley & Sons, Inc., Somerset, New Jersey) and as further discussed below.
- functionally active fragments can include those fragments that comprise one or more structural domains of a BMP6, such as a binding domain, providing said domain is capable of the desired activity.
- Protein domains can be identified using the PFAM program (Bateman A., et al., Nucleic Acids Res, 1999, 27: 260-2).
- preferred fragments are functionally active, domain- containing fragments comprising at least 25 contiguous amino acids, preferably at least 50, more preferably 75, and most preferably at least 100 contiguous amino acids of a BMP6 active domain.
- the fragment comprises the entire functionally active domain.
- the functionally active fragment or variant includes recombinant BMP6 polypeptides and functionally active fragments or variants thereof, including those encoded by a BMP6-encoding nucleic acid.
- the functionally active BMP6 polypeptide could theoretically encompass the BMP6 precursor protein (accession number P22004) (SEQ ID 1 ).
- the mature BMP6 polypeptide is believed to include amino acids 374-513 of the same.
- Functionally active fragments can include polypeptides comprising amino acids 382-513, 388-513 and 412-513 of the BMP6 precursor (SEQ ID 1 ).
- BMP6-encoding nucleic acid refers to a DNA or RNA molecule that encodes a BMP6 polypeptide.
- the BMP6 polypeptide or nucleic acid or variant or fragment thereof is from a human, but can also be a homolog or derivative thereof.
- said variant or fragment thereof has at least 70% sequence identity, preferably at least 80%, more preferably 85%, still more preferably 90%, and most preferably at least 95% sequence identity with human BMP6 or the sequence encoding BMP6 (NM 001718).
- percent (%) sequence identity with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of nucleotides or amino acids in the candidate derivative sequence identical with the nucleotides or amino acids in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2. 0al9 (Altschul et al., J. MoI. Biol. (1997) 215: 403- 410) with all the search parameters set to default values.
- the HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched.
- a % identity value is determined by the number of matching identical nucleotides or amino acids divided by the sequence length for which the percent identity is being reported.
- Percent (%) amino acid sequence similarity is determined by doing the same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation.
- a conservative amino acid substitution is one in which an amino acid is substituted for another amino acid having similar properties such that the folding or activity of the protein is not significantly affected.
- Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleucine, methionine, and valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids are arginine, lysine and histidine; interchangeable acidic amino acids are aspartic acid and glutamic acid; and interchangeable small amino acids are alanine, serine, threonine, cysteine and glycine.
- an alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman (Smith and Waterman, 1981 , Advances in Applied Mathematics 2: 482-489; database: European Bioinformatics Institute; Smith and Waterman, 1981 , J. of Molec. Biol., 147: 195-197; Nicholas et al., 1998, "A tutorial on Searching Sequence Databases and Sequence Scoring Methods” (www.psc.edu) and references cited therein; W. R. Pearson, 1991 , Genomics 11 : 635-650).
- This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff (Dayhoff: Atlas of Protein Sequences and Structure, M. O.
- Derivative nucleic acid molecules of the subject nucleic acid molecules include sequences that hybridize to the nucleic acid sequence encoding BMP6.
- the stringency of hybridization can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybridization and washing. Conditions routinely used are set out in readily available procedure texts (e.g. Current Protocol in Molecular Biology, Vol. 1 , Chap. 2.10, John Wiley & Sons, Publishers (1994); Sambrook et al., Molecular Cloning, Cold Spring Harbor (1989)).
- a nucleic acid molecule of the invention is capable of hybridizing to a nucleic acid molecule containing the nucleotide sequence of a BMP6 under high stringency hybridization conditions that are: prehybridization of filters containing nucleic acid for 8 hours to overnight at 65 C in a solution comprising 6X single strength citrate (SSC) (1X SSC is 0.15 M NaCI, 0.015 M Na citrate; pH 7.0), 5X Denhardt's solution, 0.05% sodium pyrophosphate and 100 g/ml herring sperm DNA; hybridization for 18-20 hours at 65 C in a solution containing 6X SSC, 1X Denhardt's solution, 100 ⁇ g/ml yeast tRNA and 0.05% sodium pyrophosphate; and washing of filters at 65 C for 1 hr in a solution containing 0.1X SSC and 0.1 % SDS (sodium dodecyl sulfate).
- SSC single strength citrate
- moderately stringent hybridization conditions are used that are: pretreatment of filters containing nucleic acid for 6 h at 40 C in a solution containing 35% formamide, 5X SSC, 50 mM Ths-HCI (pH7.5), 5mM EDTA, 0.1 % PVP, 0.1 % Ficoll, 1 % BSA, and 500 ⁇ g/ml denatured salmon sperm DNA; hybridization for 18-2Oh at 40 C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCI (pH7.5), 5mM
- EDTA 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100, ⁇ g/ml salmon sperm DNA, and 10% (wt/vol) dextran sulfate; followed by washing twice for 1 hour at 55 C in a solution containing 2X SSC and 0.1 % SDS.
- low stringency conditions can be used that are: incubation for 8 hours to overnight at 37 C in a solution comprising 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 ⁇ g/ml denatured sheared salmon sperm DNA; hybridization in the same buffer for 18 to 20 hours; and washing of filters in 1 x SSC at about 37 C for 1 hour.
- the method involves the application of a composition comprising a compound capable of binding to BMP6 and inactivating it.
- the present invention can relate to antagonists of BMP6.
- the compound might be an antibody or a fragment thereof which is capable of binding to BMP6.
- Antibodies that specifically bind BMP6 polypeptides can be generated using known methods.
- the antibody is specific to a mammalian ortholog of BMP6 polypeptide, and more preferably, to human BMP6.
- Antibodies may be polyclonal, monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')2 fragments, fragments produced by a FAb expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.
- Epitopes of BMP6 which are particularly antigenic can be selected, for example, by routine screening of BMP6 polypeptides for antigenicity or by applying a theoretical method for selecting antigenic regions of a protein (Hopp and Wood (1981 ), Proc. Natl. Acad. Sci. U.S.A. 78: 3824-28; Hopp and Wood, (1983) MoI. Immunol. 20: 483-89; Sutcliffe et al., (1983) Science 219: 660- 66) to the amino acid sequence of a BMP6.
- Monoclonal antibodies with affinities of 10 8 M “1 preferably 10 9 M “1 to 10 10 M “1 , or stronger can be made by standard procedures as described (Harlow and Lane, supra; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press, New York; and U. S. Pat. Nos. 4,381 ,292; 4,451 ,570; and 4,618,577).
- Antibodies may be generated against crude cell extracts of BMP6 or substantially purified fragments thereof. If BMP6 fragments are used, they preferably comprise at least 10, and more preferably, at least 20 contiguous amino acids of a BMP6 protein. BMP6-specific antigens and/or immunogens can be coupled to carrier proteins that stimulate the immune response. For example, the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, which enhances the immune response. An appropriate immune system such as a laboratory rabbit or mouse is immunized according to conventional protocols.
- KLH keyhole limpet hemocyanin
- BMP6-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding BMP6 polypeptides.
- an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding BMP6 polypeptides.
- ELISA enzyme-linked immunosorbant assay
- Other assays such as radioimmunoassays or fluorescent assays might also be used.
- Chimeric antibodies specific to BMP6 polypeptides can be made that contain different portions from different animal species.
- a human immunoglobulin constant region may be linked to a variable region of a murine mAb, such that the antibody derives its biological activity from the human antibody, and its binding specificity from the murine fragment.
- Chimeric antibodies are produced by splicing together genes that encode the appropriate regions from each species (Morrison et al., Proc. Natl. Acad. Sci. (1984) 81 : 6851 -6855; Neuberger et al., Nature (1984) 312: 604-608; Takeda et al., Nature (1985) 31 : 452-454).
- Humanized antibodies which are a form of chimeric antibodies, can be generated by grafting complementary-determining regions (CDRs) (Carlos, T. M., J. M. Harlan. 1994. Blood 84: 2068-2101 ) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., 1988 Nature 323: 323-327). Humanized antibodies contain murine sequences and human sequences, and thus further reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS, and Queen C. 1991 Nature 351 : 501-501 ; Morrison SL. 1992 Ann. Rev. Immun. 10: 239-265). Humanized antibodies and methods of their production are well-known in the art (U.S. Pat. Nos. 5,530,101 , 5,585,089, 5,693,762, and 6,180,370).
- BMP6-specific single chain antibodies which are recombinant, single chain polypeptides formed by linking the heavy and light chain fragments of the Fv regions via an amino acid bridge, can be produced by methods known in the art (U.S. Pat. No. 4,946,778; Bird, Science (1988) 242: 423-426; Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85: 5879-5883; and Ward et al., Nature (1989) 334: 544-546).
- polypeptides and antibodies of the present invention may be used with or without modification. Frequently, antibodies will be labelled by joining, either covalently or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., lnt J. Biol Markers (1989) 4: 131 -134).
- labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent emitting lanthanide metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437;
- immunoglobulins may be produced (U.S. Pat. No. 4,816,567).
- Antibodies to cytoplasmic polypeptides may be delivered and reach their targets by conjugation with membrane-penetrating toxin proteins (U.S. Pat. No. 6,086,900).
- the method involves the application of a composition comprising a compound capable of binding to ALK6 and either activating or blocking its activity.
- a compound may be a an antibody or a fragment thereof which is capable of binding to ALK6.
- the present invention can comprise agonists or antagonists of ALK6.
- an antibody might bind ALK6 and prevent the binding of BMP6, thus preventing BMP6 from activating ALK6 and driving melanogenesis or melanin transfer. Details of well known techniques of antibody generation are set out above.
- the method involves the application of a composition comprising a nucleic acid capable of modulating the expression of ALK6 or Cdc42 through interaction with DNA or RNA coding for ALK6 or Cdc42 or a functional portion thereof.
- the nucleic acid is an RNA molecule, especially an RNA molecule capable of targeted antisense interaction or RNA interference against mRNA encoding ALK6 or Cdc42_.
- RNAi molecule for targeting Cdc42 mRNA can be ⁇ '-GAUAACUCACCACUGUCCATT-S' and ⁇ '-UGGACAGUGGUGAGUUAUCTT-S' oligohbonucleotides; or 5 1 -GACUCCUUUCUUGCUUGUUTT-3 1 and
- 5'-AACAAGCAAGAAAGGAGUCTT-3Oligoribonucleotides can be used to inhibit Cdc42, or other such appropriate and specific sequence. It is within the skills of the person skilled in the art to determine other suitable sequences which would exhibit RNAi against ALK6 or Cdc42 mRNA.
- RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene.
- dsRNA double-stranded RNA
- Methods relating to the use of RNAi to silence genes in C. elegans, Drosophila, plants, and humans are known in the art (Fire A, et al., 1998 Nature 391 : 806-811 ; Fire, A. Trends Genet. 15, 358-363 (1999); Sharp, P. A. RNA interference 2001. Genes Dev. 15, 485-490 (2001 ); Hammond, S. M., et al., Nature Rev. Genet. 2,110-1119 (2001 ); Tuschl, T. Chem. Biochem.
- Nucleic acid modulators are commonly used as research reagents, diagnostics, and therapeutics. For example, antisense oligonucleotides, which are able to inhibit gene expression with extraordinar specificity, are often used to elucidate the function of particular genes (see, for example, U.S. Pat. No. 6,165,790). Nucleic acid modulators are also used, for example, to distinguish between functions of various members of a biological pathway. For example, antisense oligomers have been employed as therapeutic moieties in the treatment of disease states in animals and man and have been demonstrated in numerous clinical trials to be safe and effective (Milligan JF, et al, Current Concepts in Antisense Drug Design, J Med Chem. (1993) 36: 1923-1937; Tonkinson JL et al., Antisense Oligodeoxynucleotides as Clinical Therapeutic Agents, Cancer Invest. (1996) 14: 54-65).
- the method involves the application of a composition identified by the methods of identifying substances that affect ALK6 or Cdc42 set out below.
- the substance is an antagonist of ALK6.
- ALK6 antagonists which may be suitable for use in the present invention include sclerostin, chordin-like and follistatin- related protein (FSRP).
- FSRP chordin-like and follistatin- related protein
- the antagonist is sclerostin (SEQ ID 3).
- Small molecules are often preferred to modulate function of proteins with enzymatic function, and/or containing protein interaction domains.
- Chemical agents referred to in the art as "small molecule” compounds are typically organic, non-peptide molecules, having a molecular weight up to 10,000, preferably up to 5,000, more preferably up to 1 ,000, and most preferably up to 500 daltons.
- This class of modulators includes chemically synthesized molecules, for instance, compounds from combinatorial chemical libraries. Synthetic compounds may be rationally designed or identified based on known or inferred properties of the ALK6 protein or may be identified by screening compound libraries.
- modulators of this class are natural products, particularly secondary metabolites from organisms such as plants or fungi, which can also be identified by screening compound libraries for ALK6-modulating activity. Methods for generating and obtaining compounds are well known in the art (Schreiber SL, Science (2000) 151 : 1964-1969; Radmann J and Gunther J, Science (2000) 151 : 1947-1948).
- Small molecule modulators identified from screening assays can be used as lead compounds from which candidate clinical compounds may be designed, optimized, and synthesized.
- the activity of candidate small molecule modulating agents may be improved several- fold through iterative secondary functional validation, as further described below, structure determination, and candidate modulator modification and testing.
- candidate clinical compounds are generated with specific regard to clinical and pharmacological properties.
- the reagents may be dehvatized and re-screened using in vitro and in vivo assays to optimize activity and minimize toxicity for pharmaceutical development.
- Antagonists of ALK6 may be able to inhibit the transfer of melanin from melanocytes to keratinocytes, thereby reducing skin and/or hair pigmentation.
- agonists of ALK6 may be capable of enhancing the transfer of melanin from melanocytes to keratinocytes, thereby increasing skin and hair pigmentation. Both of these effects can be desirable from a cosmetic point of view, and additionally there may be medical benefits from such an effect. For example it is currently desirable in western Europe and the United States (and elsewhere) to have a sun tanned appearance for cosmetic reasons. In some countries of Asia it is desirable to have a relatively pale appearance for cosmetic reasons.
- melanin is involved in protecting the skin from the damaging effects of the sun, it may be desirable to increase melanin content of the skin from a protective point of view. It is preferred that the subject is a mammal, preferably a primate and especially a human.
- the present invention provides a composition
- a composition comprising a substance capable of modulating the activity or expression of ALK6 or Cdc42 for use in modulation of the pigmentation of the skin and/or hair of a subject. Details of suitable substances are provided above, and the modulation may be for cosmetic or for therapeutic purposes.
- Particularly preferred substances include BMP6 or functionally active variants or fragments thereof, and sclerostin.
- the present invention provides use of a composition comprising a substance capable of modulating the activity or expression of ALK6 or Cdc42 in the manufacture of a medicament for the treatment of a disease associated with abnormal pigmentation of the skin.
- Such treatment may be curative, or it might be in order to lessen symptoms.
- compositions according to the present inventions are suitable for topical application to the skin.
- Any common topical formulation such as a solution, suspension, gel, cream, ointment or salve and the like may be employed. Preparation of such topical formulations are described in the art of pharmaceutical formulations as exemplified, for example, by Gennaro et al. (1995) Remington's Pharmaceutical Sciences, Mack Publishing.
- the compositions could also be administered as a powder or spray, particularly in aerosol form.
- the present invention provides a method of assessing the ability of a substance to modulate the transfer of melanin from a melanocyte to a keratinocyte or potentially from keratinocyte to keratinocyte, the method comprising the steps of:
- the method involves determining the ability of a substance to bind to ALK6.
- the ALK6 may be on a cell, or it may be provided on a support.
- the method involves providing a cell expressing ALK6 and determining the ability of the test substance to interact with the ALK6 expressed by said cell, especially ALK6 expressed on the surface of the cell.
- the cell expressing ALK6 is a melanocyte.
- the method of the present invention involves determining the ability of the test substance to modulate the activity and/or expression of ALK6.
- the method may involve determining the ability of the test substance to activate ALK6, i.e. determining whether the test substance is an agonist of ALK6. In an alternative embodiment the method may involve determining the ability of the test substance to deactivate ALK6, i.e. determining whether the test substance is an antagonist of ALK6.
- test substance is capable of modulating the activity of ALK6. For example it is possible to determine the effect of the test substance on downstream signalling molecules which are effected by ALK6 activation. Alternatively, it would be possible to determine the effect of a test substance on the expression of mRNAs or proteins which are effected by ALK6 activation. This could involve determining, for example, a) recruitment of R-Smads (receptor regulated Smads, Smad-1 , -5, -8) and its subsequent phosphorylation upon binding to ALK6; b) blocking of activation of R-Smads by inhibitory Smads (I-Smads), e.g. Smads 6 and 7; or c) selective degradation of ALK6 by Smurfs (Smad ubiquitination regulatory factors).
- R-Smads receptor regulated Smads, Smad-1 , -5, -8
- I-Smads inhibitory Smads
- Smurfs Smad ubiquitination regulatory
- ALK6 ALK6 mRNA levels in the cells
- protein expression on the surface of a cell e.g. using immunofluorescence techniques, ELISA, two-dimensional electrophoresis or mass-spectrometric methods.
- the method may involve the step of determining the ability of the test substance to interact with ALK6 by determining the affect of the test substance on the expression or activation of Cdc42, preferably the expression of Cdc42.
- Methods of determining the expression of Cdc42 include measuring the amount of Cdc42 protein in or on the cell, or determining the amount of a precursor in the synthesis of Cdc42 protein, for example mRNA which codes for Cdc42. Techniques required to determine the level of expression of Cdc42 protein or Cdc42 mRNA levels would be apparent to the person skilled in the art.
- Techniques to determine protein levels may involve immunostaining (e.g., immunofluorescence, western blotting), ELISA, two-dimensional electrophoresis or mass-spectrometric methods.
- Techniques to determine mRNA levels might involve northern blotting, reverse transcriptase PCR, quantitative PCR, microarrays or Affymetrix® chips.
- the present invention is concerned with substances which are capable of interacting with ALK6 in a manner which affects melanogenesis or melanin transfer. Accordingly, determining the effect of a test substance on melanogenesis or melanin transfer is particularly desirable. Methods of achieving this are set out in detail in the present application, for example determining the effect of a substance on the number of melanosomes transferred from a melanocyte to a keratinocyte or potentially from keratinocyte to keratinocyte. This may be achieved using the immunostaining techniques described in the present application.
- the method of the present invention may involve the step of providing BMP6.
- BMP6 By providing BMP6 in the method, it is possible to determine the ability of a test substance to modulate the activity of ALK6 is the presence of its biological ligand. Such a method may be more relevant to physiological conditions as it assesses the ability of a compound to interact with ALK6 in competition with BMP6.
- the present invention provides a method of assessing the ability of a substance to modulate the transfer of melanin from a melanocyte to a keratinocyte, or potentially from keratinocyte to keratinocyte, the method comprising the steps of:
- the cell expressing Cdc42 is a melanocyte or a keratinocyte, more preferably a melanocyte.
- the method may involve comparing the activity and/or expression of Cdc42 in a cell treated with the test substance with the activity and/or expression of Cdc42 in a control cell.
- the level of expression of Cdc42 may be determined by many methods apparent to the person skilled in the art. In embodiments of the present invention the expression may be determined using immunofluorescence, western blotting or by determining the level of Cdc42 mRNA. As mentioned above, other suitable methods would be apparent to the person skilled in the art.
- Figures 1 A and B show the results of assessment of epidermal keratinocyte and epidermal melanocyte cytotoxicity to BM P6 incubation in vitro.
- BMP6 Normal human epidermal melanocytes cultures (i) Female-68; p4 and (ii) Female-42; p3 were treated 72 h with 10ng/ml and 100ng/ml of BMP6. Cytotoxicity was assessed by cell death and cytopathologic change in morphology. No cytotoxic effects can be seen.
- Figures 2 A and B show the results of detection of BMP6 and ALK6 protein expression in normal human epidermal melanocytes.
- Double-immunolabeling for (i) BMP6 (green); (ii) tyrosinase (red) and (iii) merged image of BMP6 and tyrosinase, confirming BMP6 protein expression in human epidermal melanocytes (F39-MC). (iv) shows the corresponding bright-field image.
- Figures 3 A and B show the results of quantitative analysis of dose-dependent BMP6-stimulated melanosome transfer in epidermal melanocyte-keratinocyte co-culture.
- Double-immunofluorescence was performed on matched melanocyte-keratinocyte co-cultures (F39 MC-KC) stimulated with increasing concentrations of BMP-6 for 24h (1 , 10, 50, 100 and 500 ng/ml). Double-immunolabelling with anti-gp100 antibody (green) and anti-cytokeratin antibody (red) showed a marked dose- dependent increase in the number of fluorescent spots transferred to keratinocyte. Nuclei were stained with DAPI.
- Figures 4 A and B show the result of and experiment to determine whether BMP6 up-regulates Cdc42 and ALK6 (the BMP6 receptor) expression in epidermal melanocytes.
- RT-PCR analysis of Cdc42 mRNA expression in normal human epidermal melanocyte cultures (Female 39y-MC).
- Figures 6 A and B show the results of an experiment demonstrating inhibition of BMP6-induced melanosome transfer using a selective BMP6 antagonist (Sclerostin) A.
- Double-immunofluorescence was performed on matched melanocyte-keratinocyte co-cultures (Female 36y MC-KC) in the presence or absence of recombinant human BMP6 (100 ng/ml) with or without addition of its selective antagonist, recombinant human Sclerostin (400 ng/ml) for 24h.
- FIG. 8 shows the results of an experiment demonstrating inhibition of BMP6-induced filopodia formation using a selective BMP6 antagonist (sclerostin).
- Normal human epidermal melanocyte Female 42y-EM
- recombinant human BMP6 100 ng/ml
- recombinant human Sclerostin 400 ng/ml
- Figures 9 A, B and C show the results of an experiment demonstrating the effect of BMP6 on human epidermal melanogenesis, tyrosinase activity and expression of tyrosinase at mRNA and protein levels.
- BMP bone morphogenetic protein
- BMP6-induced production of nanotubules (called filopodia) as evidenced by Scanning electron microscopic (SEM) analysis of human melanocytes. Dissecting the molecular mechanism by which BMP6 induces filopodia formation, it was found that BMP6 stimulates the expression of (cell division cycle 42) Cdc42 in a dose-dependent manner in human melanocytes using reverse transcriptase analysis. Requirements of Cdc42 in filopodia formation and melanosome transfer in melanocytes were verified using SEM analysis of FM55 cells with transfected constitutively active (CA) Cdc42 and dominant-negative Cdc42. CA- Cdc42 induces dorsal filopodia formation while DN-Cdc42 suppresses dorsal filopodia.
- CA constitutively active
- BMP6 is predicted to be synthesised as a precursor molecule which is cleaved to yield a 132 amino acid mature polypeptide with a calculated molecular weight of approximately 15 Kd.
- BMP6 precursor
- the mature form of BMP6 contains three potential N-linked glycosylation sites per polypeptide chain.
- the active BMP-6 protein molecule is likely a dimer. Processing of BMP6 into the mature form involves dimerization and removal of the N- terminal region in a manner analogous to the processing of the related protein TGF ⁇ (Gentry et al., MoI. Cell. Biol. 8: 4162 (1988).
- the human BMP6 precursor is provided in the GenBank database (accession number-P22004) and integrated into UniprotKB/Swiss-Prot (see SEQ ID NO : 1).
- the mature polypeptide is believed to include amino acids 374-513 of SEQ ID NO : 1.
- Other active BMP-6 polypeptides include polypeptides including amino acids 382- 513,388-513 and 412- 513 of SEQ ID NO : 1.
- BMPs work by binding to a receptor complex that is found on the surface of almost all normal cells, and is composed of type I and type Il receptors.
- BMPR-I when present as a monomer, binds BMP with low affinity. However, when BMPR-I
- BMP dimers initiate signaling by binding cooperatively to both type I and type Il receptors.
- Each monomer of BMP6 can connect to both type I and type Il receptors.
- the assembly of the tetrameric receptor complex is essential for transducing the signal into the cell.
- Type Il receptors are constitutively-active kinases, which transphosphorylate type I receptors upon ligand binding. However, type I receptors activate intracellular substrates by phosphorylation, and thus determine the specificity of intracellular signals.
- BMPs including BMP6 can bind to 2 type I receptors include BMPR-IA (ALK-3; Seq ID 4), and BMPR-IB (ALK6; Seq ID 2). While BMPR-IA and BMP-IB are structurally similar they show distinct spatial and temporal expression patterns.
- BMP6 induced the expression of its own cognate receptor, ALK6 (accession number O00238).
- a selective BMP6 antagonist sclerostin inhibited this BMP6-induced ALK6 expression along with Cdc42 expression in melanocytes, suggesting that Cdc42 participates in a possible amplification loop for BMP6 signalling.
- Cdc42 signal emanating from melanocyte BMP receptors is involved in filopodia formation to control melanosome transfer to keratinocytes.
- the amino acid sequence of Sclerostin is provided in the GenBank database (accession number-Q9BQB4) and integrated into UniprotKB/Swiss- Prot. (see SEQ ID NO: 3).
- the C-terminal region of SOST (amino acids 169-203 of SEQ ID 3) play a role in SOST dimerisation.
- the N-terminal region of SOST (amino acids 23-58 of SEQ ID 3) interacts with both type-l and type-ll receptor biding sites on BMP6, and a portion of the core region (amino acids 134-166 of SEQ ID 3) may interact with the type Il receptor biding site such that antibodies specific for these SOST regions may block or impair binding of BMP to SOST.
- BMP6 can induce melanogenesis by stimulating the expression and activity of the rate-limiting enzyme (tyrosinase) in melanocytes.
- BMP6 can control melanin transfer between melanocytes and keratinocytes, and potentially from keratinocytes to keratinocytes. This occurs, at least in part, through the action of Cdc42.
- BMP antagonists, and molecules based on their structure and action can be used as novel regulators of mammalian skin and hair pigmentation.
- Fully matched epidermal keratinocytes i.e. from the same skin specimen
- K-SFM keratinocyte serum-free medium
- BPE bovine pituitary extract
- BPE bovine pituitary extract
- penicillin 100 U/ml
- streptomycin 100 ⁇ g/ml
- 2 mM L-glutamine 2 mM L-glutamine
- keratinocytes and melanocytes were identified using anti-cytokeratin antibody (Abeam, Cambridge, UK) and the melanocyte-specific NKI/beteb antibody (Monosan, Uden, Netherlands) to gp100 respectively.
- melanocytes (passage 4) and keratinocytes (passage 2) were seeded onto 8-well Lab-Tek® chamber slides (ICN Biomedicals, Inc. Aurora, OH, USA) at a cell density of 1 x 10 4 cells/well and in a ratio of 1 melanocyte to 10 keratinocytes.
- Co-cultures were maintained overnight (16 h) in a mixture of K-SFM and MEM (co-culture medium) to allow cell attachment, followed by medium replenishment for a further 24 h.
- the co-cultures were incubated for 16 h in serum-starved medium (i.e., lacking foetal calf serum and bovine pituitary extract) to remove exogenous sources of growth factors, before assessing the effects of 100ng/ml recombinant human BMP-6 (R & D System, Oxfordshire, UK) and 400ng/ml recombinant human sclerostin (R & D System, Oxfordshire, UK) for 24 h.
- serum-starved medium i.e., lacking foetal calf serum and bovine pituitary extract
- MC Epidermal melanocytes
- KC epidermal keratinocytes
- the cells were switched to serum free medium (so-called starved) supplemented with 10ng/ml and 100ng/ml BMP-6 for 24h, 48h and 72h. Cytotoxicity was assessed by cell death and cytopathologic change in morphology.
- MC in a confluent T225 flask were trypsinised and seeded into T25 flask with full medium and allowed to attach overnight. 24h before treatment the medium was replaced with starved medium for 24h. Cells were washed 3-times with sterile PBS, and incubated in starved medium alone or with 10Ong/ml of BMP-6 for different time periods (1 -24 h). In a different experiment cells were treated for 12h with different concentration of BMP- 6.
- the molecular weight ladder (Magik Marker, Invitrogen) was incubated in 5% milk PBS/0.075% Tween- 20 and the membrane strips were incubated with either 1 ml of 5% milk PBS/0.075% Tween-20 (negative control), or 1 ml of rabbit anti-tyrosinase (1 :200 polyclonal antibody in 5% milk PBS/0.075% Tween 20) and 1 ml of goat anti-actin (1 :1000 polyclonal antibody in 5% milk PBS/0.075% Tween 20) on a rocking platform overnight at 4°C. After extensive washes the blots were incubated with horseradish peroxidise conjugated secondary antibodies for 2h.
- the molecular weight ladder was then incubated with 1 ml of HRP-goat anti-human IgG (H+L) (Zymed, USA) (1 :500) diluted in 5% milk PBS/0.075% Tween 20 and membrane strips were incubated in 1 ml of anti-rabbit IgG, horseradish peroxidase linked whole antibody (HRP) secondary antibody (Amersham Biosciences, UK) (1 :700 diluted in 5% milk PBS/0.075% Tween 20) on a rocking platform for 2 hours at room temperature. The washing procedure was repeated and the membrane strips were incubated in LumiGLO ® Reagent and Peroxide (BioLab Ltd, UK) for 2 minutes at room temperature.
- HRP-goat anti-human IgG H+L
- HRP horseradish peroxidase linked whole antibody
- the chemiluminescent signal was detected by exposing the blot strips to Kodak XRA X-ray film (Kodak, UK) at various exposure times, followed by development in developing solution (Kodak, UK) until bands appeared, rinsed in tap water, fixed in the fixer (Kodak, UK) until the film turned blue, then rinsed with tap water and allowed to dry.
- the membrane was then labelled and scanned for densitometric analysis for the semi-quantitative assessment of protein expression levels using analysis software (Image Master Total lab version 1.11 ).
- the second primary antibody either cytokeratin (1 :100) (Abeam, Cambridge, UK) or ⁇ -Actin (1 :100) (Santa Cruz, USA) was applied for 1 h at room temperature followed by a TRITC-conjugated secondary antibody (1 :100) (Jackson lmmunoresearch Laboratories, Inc., West Grove, USA).
- DAPI Vector Laboratories, Burlingame, CA
- Matched melanocytes-keratinocytes co-cultures were stimulated with different doses of BMP-6 and compared with unstimulated cells.
- melanosome transfer was performed by counting fluorescent gp100-positive spots within recipient keratinocytes in 5 random microscopic fields per well at 10Ox magnification (oil-immersion) in 3 independent experiments. To avoid counting melanin granules that may still be associated with melanocytes, we only counted gp100-positive spots within keratinocytes that were not in direct contact with melanocytes.
- RT-PCR Reverse transcription-polymerase chain reaction
- RNA samples were treated with deoxyhbonuclease (QIAGEN, UK), followed by determination of concentration. Then a Superscript III First-Strand synthesis for Reverse Transcription Kit (Invitrogen, California) was used to synthesize first strand cDNA. The final concentration of RNA in the reaction was 1 ⁇ g/100 ⁇ l for all samples.
- PCR was performed with QIAGEN Fast Cycling PCR kit (QIAGEN, UK) under conditions described by manufacturer. Briefly, the following cycling conditions were used: 95°C for 15 min (stagel ); 96°C for 15s; primer annealing for 15s (For Cdc 42-65°C, Tyrosinase-58°C and GAPDH-60°C); 72°C for 25s (stage 2) x 30 cycle. Primers used for RT- PCR reactions are shown in Table 1 and were obtained from Sigma- Genosys, UK. PCR products were separated over 1 % agarose gel in 1X
- GFP-Cdc42(15A) and the constitutively active GFP-Cdc42(61 L) and GFP in pEGFP-C3 were generous gifts of Richard E. Cheney (University of North Carolina, Chapel Hill). Vectors included the neomycin gene conferring resistance to geneticin (G418). Approximately 5 x 10 5 moderately pigmented FM55 cells were grown to 70-80% confluence in six well plates for 16 h in RPMI medium with 10% FBS day before transfection. FM55 cells were transfected using
- Lipfectamine 2000 Transfection Reagent (Invitrogen, Carlabad, CA, USA). Briefly, 3.2 ⁇ g of cDNA constructs was mixed with 8 ⁇ l of Lipfectamine 2000 Transfection Reagent in 1.6 ml of Opti-MEM Reduced Serum Medium. Cells were incubated with transfection mixture for 12 h, washed three times with 1X PBS, incubated in fresh RPMI containing 10% FBS for 48h. The transfected cells were selected for 15 days using 1.6 mg/ml G418. Then 1 x 10 4 stable transfected cells were cultured for 24 h in 8- well Lab-Tek® chamber slides in the presence of RPMI medium with 10% FBS.
- BM P6 (10 and 100 ng/ml) does not exhibit cytotoxicity to normal human epidermal melanocytes and keratinocytes
- BMP6 is toxic to melanocytes or keratinocytes
- cells were maintained in the presence of 10 ng/ml and 100ng/ml for 24h, 48h and 72h. Both doses of BMP6 are not associated with altered cell growth or morphology of melanocyte and keratinocytes ( Figure 1 A, 1 B).
- BMP6 in normal human melanocytes was confirmed by double immunolabeling (yellow-orange, Aiii) of anti-BMP6 (green, Ai) with anti-tyrosinase antibody (red, Aii) ( Figure 2A). Double immunolabeling of melanocytes with anti-BMP6 (green, Bi) and anti-ALK6 (Red, Bii) antibody revealed BMP6 and ALK6 co-localization (yellow, Biii) throughout the cell ( Figure 2B).
- BMP6 up-regulates Cdc42 message expression in human epidermal melanocytes
- Cdc42 a master regulator of filopodia formation in human melanocytes
- RT-PCR analysis indicated that maximum induction of Cdc42 after 100 ng/ml BMP6 treatment occurred from 2-4 h and then reduced slightly but remain elevated for up to 12h, compared with the basal level expression of Cdc42 mRNA in untreated control ( Figure 4 A).
- the induction of Cdc42 mRNA by BMP6 occurred in a dose-dependent fashion ( Figure 4B).
- BMP6- also stimulated the expression of the BMP6 receptor ALK6 (green Figure 4C ii) compared to normal basal level of expression of ALK6 ( Figure C i) in normal human epidermal melanocytes ( Figure 4C).
- Rho protein mutants Two kinds have been used extensively to analyze their functions; activated mutants, which are constitutively GTP-bound because the GTPase activating proteins (GAPs) are inhibited; and dominant-negative mutants which act by titrating out guanine nucleotide exchange factor (GEFs) (Feig 1999).
- GEFs guanine nucleotide exchange factor
- Manipulation of melanosomes transfer by over-expression or inhibition of Cdc42 further suggests the strong involvement of filopodia in melanosome transfer. Since BMP6 can up-regulate the expression of Cdc42, this suggests that BMP6-assocaited stimulation of melanosome transfer may involve Cdc42 as its downstream target. To test this we exploited the inhibitory effect of DN-Cdc42 on filopodia formation and melanosome transfer. This can also be similarly achieved by knocking down of endogenous Cdc42 expression of human melanocyte using a siRNA against human Cdc42.
- sclerostin a selective BMP6 antagonist
- sclerostin inhibits BMP-6-induced melanosome transfer
- sclerositin itself inhibited the basal level of melanosome transfer from melanocytes to keratinocytes ( Figure 6A 1 B)-
- sclerostin inhibited the BMP6-induced melanosome transfer in human epidermal melanocyte- keratinocyte co-culture suggesting that sclerostin can be used as a novel regulatior of mammalian skin and hair pigmentation (Figure 6A, B).
- BMP6 increased melanin content (by approx. 32 ⁇ 9% after 72 h) in human epidermal melanocytes in vitro (Figure 9A).
- a selective BMP6 antagonist sclerostin inhibited the BMP6-induced melanin content (by 15 ⁇ 3%), in human epidermal melanocytes (Figure 9A).
- Tyrosinase activity was also stimulated by BMP6 while Sclerostin inhibited BMP6-induced increase in tyrosinase activity (Figure 9B).
- BMP4 has been found to be act as an autocrine inhibitor of melanogenesis in normal human melanocytes by inhibiting the expression and activity of the rate-limiting enzyme (tyrosinase) in melanocytes (Yaar et al., 2006).
- tyrosinase rate-limiting enzyme
- BMP6 act as a stimulator of melanogenesis by stimulating the expression of tyrosinase at both protein and gene level (Figure 9C). While sclerostin inhibited the BMP6-induced tyrosinase expression in human epidermal melanocytes at both protein and gene level (Figure 9C).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0816507.8A GB0816507D0 (en) | 2008-09-10 | 2008-09-10 | Product and method |
GB0908498A GB0908498D0 (en) | 2009-05-18 | 2009-05-18 | Compositions and methods |
PCT/GB2009/051139 WO2010029343A2 (en) | 2008-09-10 | 2009-09-08 | Compositions and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2331057A2 true EP2331057A2 (en) | 2011-06-15 |
EP2331057B1 EP2331057B1 (en) | 2019-03-20 |
Family
ID=41718311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09736640.5A Active EP2331057B1 (en) | 2008-09-10 | 2009-09-08 | Compositions and methods for modulating skin pigmentation |
Country Status (9)
Country | Link |
---|---|
US (1) | US8883725B2 (en) |
EP (1) | EP2331057B1 (en) |
JP (1) | JP5773872B2 (en) |
CN (1) | CN102209522B (en) |
AU (1) | AU2009290625B2 (en) |
DK (1) | DK2331057T3 (en) |
ES (1) | ES2727627T3 (en) |
PT (1) | PT2331057T (en) |
WO (1) | WO2010029343A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9561167B2 (en) | 2010-11-01 | 2017-02-07 | Kao Corporation | Skin and hair color-controlling factor |
JP2015512261A (en) * | 2012-03-30 | 2015-04-27 | ザ プロクター アンド ギャンブルカンパニー | Method for generating gene expression signatures of hyperpigmentation |
US8927517B2 (en) * | 2012-04-27 | 2015-01-06 | Kao Corporation | Factors controlling skin and hair color |
KR102348045B1 (en) * | 2015-02-27 | 2022-01-11 | (주)아모레퍼시픽 | A method of predicting side effects of a whitening ingredient |
CN110092816B (en) * | 2018-01-29 | 2023-08-01 | 上海市第一人民医院 | Small molecule polypeptide for preventing and treating fibrosis and application thereof |
GB201804355D0 (en) * | 2018-03-19 | 2018-05-02 | Imperial Innovations Ltd | Wound treatment |
WO2020000470A1 (en) * | 2018-06-29 | 2020-01-02 | 深圳市博奥康生物科技有限公司 | Recombinant vector for promoting cdc42 protein overexpression and construction method thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4381292A (en) | 1980-11-14 | 1983-04-26 | The Board Of Trustees Of The Leland Stanford Jr. University | Anti-human T-lymphocyte monoclonal antibody |
US4451570A (en) | 1981-03-26 | 1984-05-29 | The Regents Of The University Of California | Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line |
US4618577A (en) | 1983-02-09 | 1986-10-21 | The Regents Of The University Of California | Human-human hybridoma, CLNH5 |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
US6165790A (en) | 1999-11-03 | 2000-12-26 | Isis Pharmaceuticals Inc. | Antisense modulation of PI3 kinase p55 gamma expression |
ATE393573T1 (en) * | 2001-06-01 | 2008-05-15 | Wyeth Corp | COMPOSITIONS FOR SYSTEMIC ADMINISTRATION OF SEQUENCES ENCODING BONE MORPHOGENESIS PROTEINS |
CA2481784A1 (en) * | 2002-04-12 | 2003-10-23 | Trustees Of Boston University | Methods for lightening skin and hair |
AU2006230434A1 (en) * | 2005-03-30 | 2006-10-05 | Wyeth | Methods for stimulating hair growth by administering BMPs |
FR2904532B1 (en) * | 2006-08-03 | 2012-10-19 | Soc Extraction Principes Actif | DERMATOLOGICAL AND / OR COSMETIC COMPOSITION CONTAINING POLYPEPTIDES OR PEPTIDES |
US20100143289A1 (en) | 2006-12-19 | 2010-06-10 | Michael Cohen | Umbilical cord stem cell secreted product derived topical compositions and methods of use thereof |
BRPI0811102A2 (en) * | 2007-05-15 | 2014-09-23 | Puretech Ventures | METHODS AND COMPOSITIONS FOR TREATING SKIN CONDITIONS |
WO2009114180A1 (en) * | 2008-03-13 | 2009-09-17 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
-
2009
- 2009-09-08 ES ES09736640T patent/ES2727627T3/en active Active
- 2009-09-08 CN CN200980144906.8A patent/CN102209522B/en active Active
- 2009-09-08 WO PCT/GB2009/051139 patent/WO2010029343A2/en active Application Filing
- 2009-09-08 AU AU2009290625A patent/AU2009290625B2/en active Active
- 2009-09-08 PT PT09736640T patent/PT2331057T/en unknown
- 2009-09-08 DK DK09736640.5T patent/DK2331057T3/en active
- 2009-09-08 EP EP09736640.5A patent/EP2331057B1/en active Active
- 2009-09-08 JP JP2011525630A patent/JP5773872B2/en active Active
- 2009-09-08 US US13/063,016 patent/US8883725B2/en active Active
Non-Patent Citations (1)
Title |
---|
See references of WO2010029343A3 * |
Also Published As
Publication number | Publication date |
---|---|
ES2727627T3 (en) | 2019-10-17 |
AU2009290625B2 (en) | 2014-12-11 |
CN102209522B (en) | 2016-04-06 |
CN102209522A (en) | 2011-10-05 |
AU2009290625A1 (en) | 2010-03-18 |
DK2331057T3 (en) | 2019-06-17 |
US20110206625A1 (en) | 2011-08-25 |
WO2010029343A3 (en) | 2010-06-10 |
PT2331057T (en) | 2019-06-25 |
JP5773872B2 (en) | 2015-09-02 |
JP2012501639A (en) | 2012-01-26 |
EP2331057B1 (en) | 2019-03-20 |
US8883725B2 (en) | 2014-11-11 |
WO2010029343A2 (en) | 2010-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8883725B2 (en) | Compositions and methods for modulating skin pigmentation | |
Hirobe | Role of keratinocyte‐derived factors involved in regulating the proliferation and differentiation of mammalian epidermal melanocytes | |
Grumolato et al. | Selenoprotein T is a PACAP‐regulated gene involved in intracellular Ca2+ mobilization and neuroendocrine secretion | |
Noblesse et al. | Lysyl oxidase-like and lysyl oxidase are present in the dermis and epidermis of a skin equivalent and in human skin and are associated to elastic fibers | |
Kuroki et al. | High glucose induces alteration of gap junction permeability and phosphorylation of connexin-43 in cultured aortic smooth muscle cells. | |
Péterfi et al. | Peroxidasin is secreted and incorporated into the extracellular matrix of myofibroblasts and fibrotic kidney | |
US20120141469A1 (en) | Cripto antagonism of activin and tgf-b signaling | |
EP3225626B1 (en) | Sfrp5-derived peptide fragment and cosmetic composition for skin whitening containing same | |
Lamoreux et al. | The pinkeyed‐dilution protein and the eumelanin/pheomelanin switch: in support of a unifying hypothesis | |
Lai et al. | Ror2-Src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE | |
Sabatel et al. | Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis | |
Rouzaud et al. | Regulation of melanocortin 1 receptor expression at the mRNA and protein levels by its natural agonist and antagonist | |
Marubashi et al. | A Varp-binding protein, RACK1, regulates dendrite outgrowth through stabilization of Varp protein in mouse melanocytes | |
Liu et al. | URB expression in human bone marrow stromal cells and during mouse development | |
KR101494375B1 (en) | Methods useful in studying or modulating skin or hair pigmentation, plant extracts for use in compositions and cosmetic care method | |
JP2016510760A (en) | Compositions and methods for reducing skin pigmentation | |
CZ292538B6 (en) | Polypeptide capable of interacting with the GAP protein SH3 domain, antibody directed against the polypeptide, nucleotide sequence encoding such polypeptide, pharmaceutical composition containing the polypeptide and use of the above antibody, polypeptide and the nucleotide | |
Voglmeir et al. | Biological and biochemical properties of two Xenopus laevis N-acetylgalactosaminyltransferases with contrasting roles in embryogenesis | |
KR101658702B1 (en) | Use of STUB1 as MITF regulator and therapeutic agent for melanin pigmented disease | |
KR100912355B1 (en) | Composition for controlling melanogenesis containing Rho GDI-?, and method for screening melanogenesis modulator using Rho GDI-? | |
KR101061479B1 (en) | Screening methods for substances that enhance the sensitivity of cancer cells to compounds or radiation | |
Nose et al. | Involvement of hydrogen peroxide in the actions of TGFβ1 | |
WO2004035627A1 (en) | Modulation of tgfbeta-like signalling pathways | |
Peters et al. | Skin-specific expression of ank-393, a novel ankyrin-3 splice variant | |
KR20140034559A (en) | Composition for preventing hair loss and enhancing hair growth comprising cyclophilin a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110404 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20130226 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 8/64 20060101ALI20180719BHEP Ipc: A61Q 19/02 20060101ALI20180719BHEP Ipc: A61Q 19/04 20060101ALI20180719BHEP Ipc: G01N 33/74 20060101ALI20180719BHEP Ipc: A61Q 5/10 20060101ALI20180719BHEP Ipc: A61K 8/60 20060101AFI20180719BHEP Ipc: A61Q 5/08 20060101ALI20180719BHEP Ipc: G01N 33/68 20060101ALI20180719BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20180905 |
|
INTG | Intention to grant announced |
Effective date: 20181004 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602009057528 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1109765 Country of ref document: AT Kind code of ref document: T Effective date: 20190415 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: MURGITROYD AND COMPANY, CH |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20190611 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 2331057 Country of ref document: PT Date of ref document: 20190625 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20190618 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190620 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190620 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190621 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1109765 Country of ref document: AT Kind code of ref document: T Effective date: 20190320 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2727627 Country of ref document: ES Kind code of ref document: T3 Effective date: 20191017 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190720 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602009057528 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20200102 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190908 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20090908 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190320 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230527 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230928 Year of fee payment: 15 Ref country code: IE Payment date: 20230921 Year of fee payment: 15 Ref country code: GB Payment date: 20230928 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20230926 Year of fee payment: 15 Ref country code: PT Payment date: 20230828 Year of fee payment: 15 Ref country code: FR Payment date: 20230921 Year of fee payment: 15 Ref country code: DK Payment date: 20230928 Year of fee payment: 15 Ref country code: DE Payment date: 20230928 Year of fee payment: 15 Ref country code: BE Payment date: 20230927 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20231019 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230926 Year of fee payment: 15 Ref country code: CH Payment date: 20231001 Year of fee payment: 15 |